Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome

Evaluation of the Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome and the Contribution of Short-chain Fatty Acids Production

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02623777

Enrollment

Registered

2015-12-08

Start date

2015-03-31

Completion date

2015-11-30

Last updated

2015-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

During this project the investigators will evaluate whether the effects of arabinoxylan oligosaccharides (AXOS) consumption on insulin resistance in participants with metabolic syndrome can be explained by the production of short-chain fatty acids (SCFA). Secondly, the investigators will evaluate whether changes in gut hormone production might explain the effect on insulin resistance.

Interventions

DIETARY_SUPPLEMENTArabinoxylan oligosaccharides

Arabinoxylan oligosaccharides administered

DIETARY_SUPPLEMENTShort chain fatty acids

Short chain fatty acids administered

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age between 18 and 65 years * Regular diet (3 meals/day on at least 5 days/week) * Central obese (defined as waist circumference ≥ 94cm for Europid men and ≥ 80cm for Europid women, with ethnicity specific values for other groups) * Insulin resistant: HOMA-IR \> 1.7 or fasting glucose \> 100mg/dL * And one of the following three factors: * Elevated TG level: ≥ 150 mg/dL (1.7 mmol/L) * Decreased HDL cholesterol level: \< 40 mg/dL (1.03 mmol/L\*) in males and \< 50 mg/dL (1.29 mmol/L\*) in females * Elevated blood pressure (BP): systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg

Exclusion criteria

* Low calorie diet or other special diet during the study or during the last month prior to the study * Serious chronic disease of the gastrointestinal tract, such as inflammatory bowel disease (Crohn's disease or ulcerative colitis), irritable bowel syndrome, chronic constipation (less than 3 bowel movements a week), chronic frequent diarrhoea (more than 3 stools a day), clinically relevant lactose intolerance, … * Use of antibiotics during the last month before starting the study * Abdominal surgery in the past (except from appendectomy) * Use of medication that affects the gastro-intestinal tract during the last 2 weeks prior to the study including spasmolytics, anti-diarrhoea medication, anti-constipation medication, and/or pre- or probiotic supplements (e.g. lacteol, Enterol) * Pregnancy, pregnancy desire or lactation * Diabetes (type 1 or 2), i.e. HbA1c \> 6.5 % * Abnormal haemoglobin (Hb) levels in blood, men must have an Hb level between 14.0 and 18.0 g / dL and women between 12.0 and 16.0 g / dL.

Design outcomes

Primary

Measure	Time frame
Change in insulin resistance after both interventions using the homeostatic model assessment for insulin resistance	2 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026